Salute e Benessere

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy ®(semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity...
Nasdaq GlobeNewswire
15/08/2025

Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR |…

Browse in-depth TOC on "Epigenetics Market" Browse in-depth TOC on "Epigenetics Market" 365 - Tables 45 - Figures 353 - Pages By offering,the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome...
PR Newswire
15/08/2025

EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress…

A Global Call to Action Antibiotic allergy mislabelling affects millions worldwide. Inaccurate labels lead to avoidance of first-line treatments and overuse of second-line antibiotics, fuelling AMR. EAACI calls on all stakeholders to promote accurate diagnosis and responsible antibiotic use.“We are launching a movement — not a moment,” said Maria Torres, EAACI President. “Too many lives are impacted by unverified allergy labels that limit treatment options and worsen health outcomes...
Nasdaq GlobeNewswire
15/08/2025

Aino Health AB (publ): interim report january-june 2025

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Increased turnover. Positive EBITDA.January - June 2025Turnover totalled 14 848 (12 230) TSEKProfit after financial items -1 141 (-4 960) TSEK Earnings per share -0,0 (-0,1) SEKApril - June 2025Turnover totalled 7 471 (6 236) TSEKProfit after financial items -587 (-2 017) TSEK Earnings per share -0,0 (-0,0) SEK The second quarter of...
Nasdaq GlobeNewswire
15/08/2025

Vistin Pharma ASA: Second quarter and YTD 2025 financial results

thof August 2025Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025.Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue was driven by 17% higher sales volume. Revenue for first half of 2025 ended at MNOK 233 compared to MNOK 210 YTD last year, an increase of 11%.Second quarter EBITDA ended at MNOK 30 compared to MNOK 27 in Q2 2024, representing 11% increase. EBITDA was positively affected...
Nasdaq GlobeNewswire
15/08/2025

Santhera extends Highbridge convertible bond to 30th September 2025

Ad hoc announcement pursuant to Art. 53 LRA Pratteln, Switzerland , 15 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that by mutual agreement the Company and Highbridge Capital Management, LLC (Highbridge) have decided to extend the maturity date of the existing CHF 7 million private convertible bond, that has a strike price of CHF 10.00, to 30 thSeptember 2025. About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company...
Nasdaq GlobeNewswire
15/08/2025

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven…

Key Takeaways from the Pediatric Relapsed/Refractory Neuroblastoma Market Report Key Takeaways from the Pediatric Relapsed/Refractory Neuroblastoma Market Report Discover the pediatric relapsed/refractory neuroblastoma new treatment @New Treatments for Pediatric Relapsed/Refractory Neuroblastoma Pediatric Relapsed/Refractory Neuroblastoma Market Dynamics The pediatric relapsed/refractory neuroblastoma market dynamics are expected to change in the coming years. The pediatric...
PR Newswire
14/08/2025

Interleukin-23 Inhibitors Market to Surge During the Forecast Period (2025-2034)…

Key Takeaways from the Interleukin-23 Inhibitors Market Report Key Takeaways from the Interleukin-23 Inhibitors Market Report Discover which indication is expected to grab the major interleukin-23 inhibitors market share @Interleukin-23 Inhibitors Market Report Interleukin-23 Inhibitors Market Dynamics The interleukin-23 inhibitors market has seen significant growth in recent years, driven primarily by theincreasing global burden of autoimmune diseasessuch as psoriasis,...
PR Newswire
14/08/2025

Dried Plasma Innovation Addresses Critical Global Need

First-in-Human Trial Demonstrates FrontlineODP™ Spray Dried Plasma Safety First-in-Human Trial Demonstrates FrontlineODP™ Spray Dried Plasma Safety Velico recently completed its first-in-human Phase Imulti-center clinical trial of FrontlineODP™ Spray Dried Plasma in healthy volunteers. The dose-escalation study with a randomized, crossovercohort demonstrated the safety of the spray dried plasma, with no serious adverse events or safety signals reported. "This trial marks the...
PR Newswire
14/08/2025

Synergy Spine Solutions Appoints Troy Wahlenmaier as Chief Commercial Officer

Mr. Wahlenmaier joins Synergy following a distinguished 13-year tenure at SI-BONE, where he served as Senior Vice President of U.S. Sales. Under his leadership, SI-BONE's U.S. revenue grew an average of 20% annually, reaching a projected $188 million in 2025. He built and led a commercial team of over 200 professionals and a robust distributor network, while also playing a key role in delivering SI-BONE's first quarter of positive Adjusted EBITDA and cash flow breakeven - marking a major…
PR Newswire
14/08/2025

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal…
PR Newswire
14/08/2025

Tecan issues CHF 150 million straight bond

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Männedorf, Switzerland, August 14, 2025 –Today, the Tecan Group (SIX Swiss Exchange: TECN) successfully raised CHF 150 million through the issuance of a fixed rate domestic straight bond. The bonds will be issued at 100.195%, with a coupon of 0.850% and a duration of 5 years...
Nasdaq GlobeNewswire
14/08/2025

Press release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 14 August 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below…
Nasdaq GlobeNewswire
14/08/2025

Enterprise Imaging IT Market worth US$4.12 Billion by 2030 with 12.2% CAGR |…

Browse in-depth TOC on "Enterprise Imaging IT Market" Browse in-depth TOC on "Enterprise Imaging IT Market" 434 - Tables54 - Figures411 - Pages By function,the market is divided into vendor-neutral archives (VNA), picture archiving and communication systems (PACS), image exchange, universal viewer, workflow orchestration, analytics, and other functions. The VNA segment is anticipated to expand at a considerable CAGR throughout the forecast period. The VNA market is...
PR Newswire
14/08/2025

Wearable Medical Devices Market to Grow at a CAGR of 20.5% from 2025 to 2032 |…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/wearable-medical-devices-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/wearable-medical-devices-market Wearable Medical Devices Market Key Growth Drivers Surge in prevalence of chronic diseases such as diabetes, cardiovascular disorders, and hypertension is fueling demand for wearable medical devices. These devices enable continuous health monitoring, early detection, and real-time data...
PR Newswire
14/08/2025

Lateral Flow Assays Market worth $12.52 billion by 2030 with 8.0% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133 Browse in-depth TOC on "Lateral Flow Assays Market" 603 - Tables59 - Figures439 - Pages By technique,the lateral flow assay kits and reagents market is segmented into competitive, sandwich, and multiplex detection assays. Sandwich assays dominated the market, with a share in 2024...
PR Newswire
14/08/2025

Anand Chandarana appointed new President of Business Unit Health & Medical

"I am very pleased to welcome Anand Chandarana as the new President of Business Unit Health & Medical. With his broad experience from sales, marketing, innovation and M&A and his strong track record of enabling an organization to accomplish commercial success, Anand is the right person to lead the business unit into its next phase of profitable growth", says Ulrika Kolsrud, President and CEO of Essity "I am very pleased to welcomeAnand Chandaranaas the new President of…
PR Newswire
14/08/2025

Home Healthcare Market is Estimated to Reach USD 539.58 Billion by 2032 |…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/home-healthcare-market Get a Free Sample Report-https://www.skyquestt.com/sample-request/home-healthcare-market Home Healthcare Market Key Growth Drivers The home healthcare industry is experiencing a great deal of innovation. Technology like telemedicine and remote patient monitoring are also driving innovation in the market. For instance, inAugust 2024, LG and Amwell unveiled the Carepoint TV Kit, which adds...
PR Newswire
14/08/2025

TraceLink Accelerates Supply Chain Transformation with New OPUS Platform…

Individually, they drive change. Together, they empower companies to digitalize and orchestrate critical business processes end-to-end, slashing operational costs, ensuring seamless regulatory compliance, and unlocking new commercial opportunities through new market and customer network expansion. Individually, they drive change. Together, they empower companies to digitalize and orchestrate critical business processes end-to-end, slashing operational costs, ensuring seamless regulatory...
PR Newswire
14/08/2025

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients living with Multiple System Atrophy (MSA) at Brigham and Women’s Hospital in Boston, Massachusetts.MSA is a rare, rapidly progressive...
Nasdaq GlobeNewswire
14/08/2025

Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate…

The development of new antibody-based therapies is traditionally a complex, time-consuming, and expensive process. Zifo's Antibody Engineering app directly confronts this challenge by integrating state-of-the-art AI into a seamless, end-to-end workflow that promises to improve the hit rate for high-affinity therapeutic antibodies. The development of new antibody-based therapies is traditionally a complex, time-consuming, and expensive process. Zifo's Antibody Engineering app directly…
PR Newswire
14/08/2025

Evaxion announces business update and second quarter 2025 financial results

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2025 financial results. Business highlights (since last quarterly update)Evaxion continues to execute its strategy and plans with a number of significant achievements across the company in recent months. We remain on track to achieve the milestones set for 2025. Highlights include: Continued strong execution of...
Nasdaq GlobeNewswire
14/08/2025

Infectious Disease Therapies Market Projected to Reach $101 Billion by End of…

This report analyzes the global market for infectious disease therapeutics, vaccines, and diagnostics, covering diseases such as HIV, influenza, hepatitis B and C, RSV, TB, HSV, malaria, rotavirus, and viral hemorrhagic fevers. It highlights market trends, challenges, and opportunities, along with insights into new products, acquisitions, collaborations, and ESG developments. The report also ranks leading companies by market share and provides detailed profiles of them. Excluded from the report…
PR Newswire
14/08/2025

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a webcast presentation of its second quarter 2025 results, on Wednesday, August 20, 2025 . The presentation can be followed as a live webcast accessed through a link on www.zelluna.com at 09:00 CET on Wednesday, August 20, 2025. The webcast presentation will be available on the Zelluna website,...
Nasdaq GlobeNewswire
14/08/2025
Altri  Comunicati